Pancreatitis is inflammation of the pancreas that may be acute or chronic and can cause severe abdominal pain, digestive dysfunction, and systemic complications.
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
Updated pediatric hypertriglyceridemia guidance says triglyceride thresholds below 400 mg/dL mainly signal ASCVD risk, while levels above about 885 mg/dL raise pancreatitis risk. Lifestyle changes remain first-line treatment, and pediatric-specific evidence for drug therapy is still limited.
A new four-marker blood test detects pancreatic cancer with 91.9% accuracy across all stages and 87.5% accuracy for early-stage disease. The test combines two newly identified proteins with existing biomarkers and can differentiate cancer from non-cancerous conditions. While promising for pancreatic cancer, most cancers still cannot be reliably diagnosed with blood tests alone.
Bariatric surgery procedures have fallen 46.4% since 2022 as prescriptions for semaglutide and tirzepatide rose to 24.17% of eligible adults by Q3 2025, though 75.8% of eligible patients still receive no treatment.
Researchers unveil pancreatic-targeted lipid nanoparticles using capsule filtration mechanisms, while a contract research organization expands lipid-based vector development services for organ-selective mRNA delivery.
Clinical studies demonstrate GLP-1 receptor agonists like semaglutide and tirzepatide produce substantial weight loss when combined with lifestyle changes, with patients achieving mean reductions of 14.9% body weight over 68 weeks.
UK and Brazil issue warnings about possible pancreatitis link to GLP-1 weight-loss drugs, while WADA monitors their use in Olympic athletes amid concerns about muscle loss and performance effects.
New research shows semaglutide cuts cardiovascular event risk by 4% per 5kg weight loss, with two-thirds of heart benefits unexplained by weight reduction alone. Study of 17,604 participants suggests multiple protective mechanisms beyond weight loss.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07599605 |
Prophylaxis Against Post-Endoscopic Retrograde Cholangio-Pancreatography Pancreatitis. |
COMPLETED | PHASE3 |
| NCT07455227 |
ERCP Management in Mild Gallstone-Induced Pancreatitis Patients Declining Subsequent Cholecystectomy : a Randomized Control Trial. |
NOT_YET_RECRUITING | NA |
| NCT07381478 |
3°C Saline Injection at the Duodenal Papilla to Prevent Post-ERCP Pancreatitis |
COMPLETED | PHASE2/PHASE3 |
| NCT07330284 |
Cold Water Irrigation Therapy as an Adjunct to Indomethacin for Post-Endoscopic Retrograde Cholangiopancreatography(ERCP) Pancreatitis |
RECRUITING | NA |
| NCT07262957 |
Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA) |
RECRUITING | PHASE4 |
| NCT07184593 |
Nucleosome Monitoring Relevance for Outcome Prediction in Critically Ill Patients |
NOT_YET_RECRUITING | |
| NCT07177599 |
Pancreatic Disease Burden in Older Adults (1990-2040) |
COMPLETED | |
| NCT07174609 |
Scrambler Therapy in Chronic Pancreatitis |
RECRUITING | NA |
| NCT07173257 |
PROMs After Pancreatectomy |
RECRUITING | |
| NCT07131917 |
Bedside Monitoring of Microenvironmental Changes in Infected Pancreatic Collections |
NOT_YET_RECRUITING | NA |
